|
T31411
|
DHA-37
DHA 37
|
|
|
|
DHA-37 is an inducer of autophagic cell death through upregulation of HMGB1 in A549 cells. |
|
T38127
|
pNPS-DHA
|
|
|
|
pNPS-DHA is an arylamide derivative of docosahexaenoyl ethanolamide that has anti-allergic activity.1It inhibits degranulation of RBL-2H3 mast cells (IC50= 15 μM).pNPS-DHA (1,000 mg/kg) inhibits IgE-dependent passive cutaneous anaphylaxis (PCA) in mice.
1.Kim, I.-H., Kanayama, Y., Nishiwaki, H., et al.Structure-activity relationships of fish oil derivatives with anti-allergic activity in vitro and in vivoJ. Med. Chem.62(21)9576-9592(2019) |
|
T11079
|
NMI 8739
n-docosahexaenoyl dopamine,Dha-DA conjugate
|
Dopamine Receptor |
GPCR/G Protein;
Neuroscience |
|
NMI 8739 (n-docosahexaenoyl dopamine) 是 D2 自身受体的激动剂。 NMI 8739 减少 NO 的产生并引起 CCL-20、MCP-1 和 IL-6 释放的浓度依赖性抑制。 |
|
T70006
|
DHA-paclitaxel
|
|
|
|
DHA-paclitaxel, also know as Taxoprexin, is prodrug comprised of the naturally occurring omega-3 fatty acid docosahexaenoic acid (DHA) covalently conjugated to the anti-microtubule agent paclitaxel. Because tumor cells take up DHA, DHA-paclitaxel is delivered directly to tumor tissue, where the paclitaxel moiety binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. Paclitaxel also induces apoptosis by binding to and blocking the func... |
|
T19294
|
Docosahexaenoic Acid methyl ester
二十二六烯酸甲酯,Methyl docosahexaenoate,all cis-DHA methyl ester
|
Others |
Others |
|
Docosahexaenoic Acid methyl ester (all cis-DHA methyl ester) 是甲基化的二十二碳六烯酸类似物，能够插入膜磷脂中而不被氧化或水解。 |
|
T64367
|
Fmoc-Dha-OH
2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)prop-2-enoic acid
|
Others |
Others |
|
Fmoc-Dha-OH (2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)prop-2-enoic acid) 是一种生物活性化合物，是肽和蛋白质合成的重要组成部分。它常用于合成基于肽的药物，也用于蛋白质-蛋白质相互作用、蛋白质折叠和蛋白质工程的研究。 |
|
T70005
|
LY3325656
|
|
|
|
LY3325656 is a GPR142 agonist suitable for clinical testing in human. LY3325656 demonstrated anti-diabetic benefits in pre-clinical studies and
ADME/PK properties suitable for human dosing. LY3325656 is the first GPR142 agonist molecule advancing to phase 1 clinic trials for the treatment of Type 2 diabetes. |
|
T74235
|
DHAPC
|
|
|
|
DHAPC 是一种对氧化非常敏感的磷脂。 |
|
T39805
|
LDHA-IN-3
PSTMB,1-(phenylseleno)-4-(trifluoromethyl) benzene
|
Dehydrogenase |
Metabolism |
|
LDHA-IN-3 (1-(phenylseleno)-4-(trifluoromethyl) benzene) 是一种有效的非竞争性乳酸脱氢酶(LDHA) 抑制剂，IC50值为 145.2 nM。LDHA-IN-3 是一种硒苯化合物，可用于研究癌症。 |
|
T3175
|
LDHA-IN-4
AZ 33,AZ-33,LDHA Inhibitor,AZ33
|
Dehydrogenase |
Metabolism |
|
LDHA-IN-4 (AZ33) 是乳酸脱氢酶 A 选择性抑制剂，IC50=0.5 μM，Kd=0.093 μM。 |
|
T36606
|
(±)7-HDHA
|
|
|
|
(±)7-HDHA is an autoxidation product of docosahexaenoic acid (DHA) in vitro. It is also produced from incubations of DHA in rat liver, brain, and intestinal microsomes. Enzymatic transformation of DHA by RBL-1 cells and human neutrophils also produces 7-HDHA. However, the enzymatic product is most likely the S-isomer. (±)7-HDHA is a potential marker of oxidative stress in brain and retina where DHA is an abundant polyunsaturated fatty acid. |
|
T36602
|
(±)4-HDHA
|
|
|
|
(±)4-HDHA is an autoxidation product of docosahexaenoic acid (DHA) in vitro. It is also produced from incubations of DHA in rat liver, brain, and intestinal microsomes. Enzymatic transformation of DHA by RBL-1 cells also produces 4-HDHA. However, the enzymatic product is most likely the S-isomer. (±)4-HDHA is a potential marker of oxidative stress in brain and retina where DHA is an abundant polyunsaturated fatty acid. |
|
T35508
|
(±)13-HDHA
|
|
|
|
(±)13-HDHA is an autoxidation product of docosahexaenoic acid (DHA) in vitro. It is also produced from incubations of DHA in rat liver, brain, and intestinal microsomes. Fresh water hydra was shown to metabolize DHA to 13(R)-HDHA, presumably via the 11R-lipoxygenase activity. (±)13-HDHA is a potential marker of oxidative stress in brain and retina where DHA is an abundant polyunsaturated fatty acid. |
|
T36042
|
17(R)-HDHA
|
|
|
|
Resolvins are a group of polyhydroxylated metabolites of docosahexaenoic acid (DHA) found in the inflammatory exudates of aspirin-treated experimental animals. 17(R)-HDHA is the primary oxygenation product of DHA when exposed to aspirin-inhibited cyclooxygenase-2. 17(R)-HDHA serves as a precursor to resolvins and has intrinsic biological activity, such as the inhibition of TNFα-induced IL-1β expression in human glioma cells. |
|
T35505
|
(±)11-HDHA
|
|
|
|
(±)11-HDHA is an autoxidation product of docosahexaenoic acid (DHA) in vitro. It is also produced from incubations of DHA in rat liver, brain, and intestinal microsomes. DHA is metabolized to 11(S)-HDHA by human platelets and canine retina. In addition to 11(S)-HDHA, 14(S)-HDHA is also produced by platelets. 11(S)-HDHA was shown to be an inhibitor of U-46619-induced human platelet aggregation and rabbit and rat aortic smooth muscle contraction with IC50 values of about 50, 4.7, and 7.5 μM, respe... |
|
T35512
|
(±)16-HDHA
|
|
|
|
(±)16-HDHA is an autoxidation product of docosahexaenoic acid (DHA) in vitro. It is also produced from incubations of DHA in rat liver, brain, and intestinal microsomes. (±)16-HDHA is a potential marker of oxidative stress in brain and retina where DHA is an abundant polyunsaturated fatty acid. |
|
T36607
|
(±)8-HDHA
|
|
|
|
(±)8-HDHA is an autoxidation product of docosahexaenoic acid (DHA) in vitro. It is also produced from incubations of DHA in rat liver, brain, and intestinal microsomes. (±)8-HDHA is a potential marker of oxidative stress in brain and retina where DHA is an abundant polyunsaturated fatty acid. |
|
T35509
|
(±)14-HDHA
|
|
|
|
(±)14-HDHA is an autoxidation product of docosahexaenoic acid (DHA) in vitro. It is also produced from incubations of DHA in rat liver, brain, and intestinal microsomes. DHA is metabolized to 14(S)-HDHA by human platelets along with 11(S)-HDHA. 14(S)-HDoHE is also produced by salmon gills upon stimulation with calcium ionophore. 14(S)-HDHA was shown to be an inhibitor of U-46619-induced human platelet aggregation and rabbit and rat aortic smooth muscle contraction with IC50 values of about 70, 3... |
|
T35504
|
(±)10-HDHA
|
|
|
|
(±)10-HDHA is an autoxidation product of docosahexaenoic acid (DHA) in vitro.[1][2] It is also produced from incubations of DHA in rat liver, brain, and intestinal microsomes.[3][4][5] (±)10-HDHA is a potential marker of oxidative stress in brain and retina where DHA is an abundant polyunsaturated fatty acid.
Reference：[1]. VanRollins, M., and Murphy, R.C. Autooxidation of docosahexaenoic acid: Analysis of ten isomers of hydroxydocosahexaenoate. J. Lipid Res. 25(5), 507-517 (1984).[2]. Reynaud, ... |
|
T36601
|
(±)17-HDHA
|
|
|
|
(±)17-HDHA is an autoxidation product of docosahexaenoic acid in vitro. It is also produced from incubations of DHA in rat liver, brain, and intestinal microsomes. 17(S)-HDHA could be produced by enzymatic oxidation of DHA using soybean lipoxygenase (LO) and is the putative product of mammalian 15-LOs. 17(S)-HDHA was shown to be an inhibitor of U-46619 -induced rabbit and rat aortic smooth muscle contraction with IC50 values of 4.9 and 7.2 μM, respectively. (±)17-HDHA is a potential marker of ox... |
|
T35997
|
22-HDHA
|
|
|
|
22-HDHA is an oxidation product of docosahexaenoic acid . In vitro, it is formed upon incubation of rat liver microsomes with DHA and NADPH and also by the human cytochrome P450 (CYP) isoform CYP4F3B in BTI-TN-5B1-4 microsomes. Serum levels of 22-HDHA increase following dietary DHA supplementation in humans. |
|
T37488
|
10(S),17(S)-DiHDHA
|
|
|
|
Protectin D1 (also known as neuroprotectin D1 when produced in neuronal tissues) is a DHA-derived dihydroxy fatty acid that exhibits potent protective and anti-inflammatory activities. 10(S),17(S)-DiHDHA is a DHA metabolite, also referred to as protectin DX (PDX). It is produced by an apparent double lipoxygenase (LO)-mediated reaction in murine peritonitis exudates, in suspensions of human leukocytes, or by soybean 15-LO incubated with DHA. It differs from protectin D1 with respect to the stere... |
|
T37259
|
14(S)-HDHA
|
|
|
|
Docosahexaenoic acid is a nutritionally-derived ω-3 fatty acid that is abundant in the brain and the retina and is thought to be important in early development and for therapeutic approaches to inflammatory disorders and cancer. 14(S)-HDHA is an oxygenation product of DHA that serves as a precursor to maresin 1 , an anti-inflammatory, pro-resolving mediator that prevents polymorphonuclear neutrophil (PMN) infiltration and stimulates macrophage phagocytosis. At doses as low as 0.2 ng/mouse 14(S)-... |
|
T73222
|
LDHA-IN-5
|
|
|
|
LDHA-IN-5为新型且有效的GO/LDHA双重抑制剂，旨在治疗原发性高草酸尿。 |
|
T61339
|
LDHA/PDKs-IN-1
|
|
|
|
LDHA/PDKs-IN-1 (compound 20e) is a highly effective dual inhibitor of PDKs and LDHA, displaying IC50 values of 0.8 μM and 0.15 μM, respectively. It significantly suppresses A549 cell proliferation (EC50 = 13.2 μM), reduces lactate formation, and enhances oxygen consumption. This compound holds great promise for cancer research [1]. |
|
T24939
|
Virodhamine trifluoroacetate
Virodhamine-trifluoroacetate,Virodhamine trifluoroacetate salt
|
|
|
|
Virodhamine trifluoroacetate is an antagonist of endogenous cannabinoid receptor mixed that acts by being a full agonist at GPR55 and CB2 and partial antagonist at CB1. |
|
T64371
|
Virodhamine
O-arachidonoyl ethanolamine
|
Cannabinoid Receptor |
GPCR/G Protein |
|
Virodhamine (O-arachidonoyl ethanolamine) 是一种内源性大麻素，是CB1受体的拮抗剂和CB2受体的激动剂。Virodhamine 可用于阿尔茨海默病等神经系统疾病的研究。 |
|
T60995
|
LDHA/PDKs-IN-2
|
|
|
|
LDHA/PDKs-IN-2 (compound 20k) 是有效的 LDHA 和 PDKs 的双重抑制剂，IC50 值分别为 0.7 和 1.6 μM。LDHA/PDKs-IN-2 会增加耗氧量并且减少乳酸的形成。LDHA/PDKs-IN-2 显示了癌症研究的潜力，它可以减少 A549 细胞的增殖，EC50值为 15.7 μM。 |
|
T35947
|
17(S)-HDHA
|
|
|
|
17(S)-HDHA is a primary mono-oxygenation product of docosahexaenoic acid in human whole blood, human leukocytes, and mouse brain. 17(S)-HDHA serves as a precursor to 17(S)-resolvins and has intrinsic biological activity, such as the inhibition of TNF-α-induced interleukin-1β expression in human glioma cells and inhibition of TNF-α-induced leukocyte trafficking to the mouse air pouch. |
|
T30217
|
Avadharidine
|
|
|
|
Avadharidine is a biochemical. |
|
T19319
|
Ethyl docosa-4,7,10,13,16,19-hexaenoate
|
Others |
Others |
|
Ethyl cis-4,7,10,13,16,19-Docosahexaenoate, the ethyl ester of Docosahexaenoate (DHA), is selectively enriched in the ethyl ester fraction through the alcoholysis process involving fatty acid ethyl esters from tuna oil and lauryl alcohol. |
|
T74757
|
Didocosahexaenoin
|
|
|
|
Didocosahexaenoin 是一种 omega-3 衍生物，是 DHA 的甘油二酯，可由 DHA 甘油三酯合成。Didocosahexaenoin 导致线粒体膜电位显着丧失并诱导 ROS 产生。Didocosahexaenoin 诱导细胞凋亡。Didocosahexaenoin 在人前列腺癌细胞中诱导比 DHA 更强的细胞毒性。 |
|
T37532
|
Docosahexaenoyl Glycine
|
|
|
|
The ω-3 polyunsaturated fatty acids (PUFAs) found in fish oils provide cardiovascular benefits. Docosahexaenoic acid (DHA), a C22:6 PUFA, is the most abundant ω-3 fatty acid in neural tissues, especially in the retina and brain. It can be synthesized from other dietary ω-3 PUFAs or taken as a nutritional supplement. Docosahexaenoyl glycine consists of DHA with glycine attached at its carboxy terminus. |
|
T31218
|
DBHDA
|
|
|
|
DBHDA is a reagent to convert a Cys into a Dha moiety by reacting with a C-terminal Cys residue and thus allowing the use of recombinant Ubl G76C mutants to prepare probes. |
|
T36002
|
4-hydroxy Hexenal
4-HHE,4-hydroxy Hexenal
|
|
|
|
4-hydroxy Hexenal is a lipid peroxidation product derived from oxidized ω-3 fatty acids such as DHA. [1][2] |
|
T36868
|
4-oxo Docosahexaenoic Acid
|
|
|
|
4-oxo Docosahexaenoic acid (4-oxo DHA) is a putative metabolite of DHA with antiproliferative and PPARγ agonist activity. It inhibits the growth of several triple negative breast cancer cell lines (MCF-10F, trMCF, bsMCF, MDA-MB-231, and BT549) at 50-100 μM, however it increased proliferation of MCF-7 cells. 4-oxo DHA binds covalently to PPARγ and activates gene transcription in luciferase reporter assays and in dendritic cells with EC50 values of approximately 8-16 μM. |
|
T35493
|
(±)10(11)-EpDPA
|
|
|
|
Cytochrome P450 metabolism of polyunsaturated fatty acids produces numerous bioactive epoxide regioisomers. (±)10(11)-EpDPA is a docosahexaenoic acid epoxygenase metabolite, derived via epoxidation of the 10,11-double bond of DHA. It has been detected in rat brain and spinal cord, as well as human serum, and acts as a substrate for soluble epoxide hydrolase with a Km value of 5.1 μM. (±)10(11)-EpDPA and other epoxy metabolites of DHA are reported to demonstrate antihyperalgesic activity in infla... |
|
T41059
|
Resolvin D3
RvD3
|
|
|
|
Resolvin D3 (RvD3) is a dysregulated mediator originating from docosahexaenoic acid (DHA). It plays a crucial role in reducing arthritic inflammation. |
|
T37238
|
(±)19(20)-EpDPA
|
|
|
|
EDHF (endothelium-derived hyperpolarizing factor) is an unidentified mediator released from vascular endothelial cells in response to acetylcholine and bradykinin which is distinct from the NOS- (nitric oxide) and COX-derived (prostacyclin) vasodilators. Cytochrome P450 (CYP450) metabolism of polyunsaturated fatty acids produces epoxides such as (±)14(15)-EpETrE which are prime candidates for the actual active mediator. However, the CYP450 metabolites of eicosapentaenoic acid and docosahexaenoic... |
|
T37225
|
(±)7(8)-DiHDPA
|
|
|
|
(±)7(8)-DiHDPA is a major metabolite of docosahexaenoic acid that is produced via oxidation by cytochrome P450 epoxygenases. Epoxygenase metabolites of DHA, including (±)7(8)-DiHDPA, suppress aggregation and thromboxane synthesis in isolated platelets. |
|
T35495
|
(±)13(14)-DiHDPA
|
|
|
|
(±)13(14)-DiHDPA is a metabolite of docosahexaenoic acid that is produced via oxidation by cytochrome P450 epoxygenases. Epoxygenase metabolites of DHA, including (±)13(14)-DiHDPA, are reported to inhibit angiogenesis, tumor growth, and metastasis. |
|
T12707
|
Resolvin D2
RvD2
|
Others |
Others |
|
Resolvin D2 is a docosahexaenoic acid (DHA) metabolite, with anti-inflammatory and anti-infective activities. |
|
T35496
|
(±)13(14)-EpDPA
|
|
|
|
Cytochrome P450 metabolism of polyunsaturated fatty acids produces numerous bioactive epoxide regioisomers. (±)13(14)-EpDPA is a docosahexaenoic acid epoxygenase metabolite, derived via epoxidation of the 13,14-double bond of DHA. It has been detected in rat brain and spinal cord and is a preferred substrate for soluble epoxide hydrolase with a Km value of 3.2 μM. (±)13(14)-EpDPA demonstrates antihyperalgesic activity in inflammatory and neuropathic pain models. (±)13(14)-EpDPA and other epoxy m... |
|
T37235
|
(±)16(17)-EpDPA
(±)16,17-EpDPE,(±)16,17 EDP,(±)16,17-epoxy Docosapentaenoic Acid,(±)16,17-epoxy DPA,(±)16(17)-EpDPA
|
|
|
|
EDHF (endothelium-derived hyperpolarizing factor) is an unidentified mediator released from vascular endothelial cells in response to acetylcholine and bradykinin which is distinct from the NOS- (nitric oxide) and COX-derived (prostacyclin) vasodilators.[1],[2]Cytochrome P450 (CYP450) metabolism of polyunsaturated fatty acids produces epoxides such as (±)14(15)-EET which are prime candidates for the actual active mediator.[3] However, the CYP450 metabolites of eicosapentaenoic acid and docosahex... |
|
T37503
|
Maresin 2
3R,14S-diHDHA
|
|
|
|
Docosahexaenoic acid is an ω-3 fatty acid that is abundant in the brain and the retina and is known to be important in early development.[1] [2] Maresin 2 (MaR2) is a 13R,14S-dihydroxy DHA formed by recombinant human macrophage 12-lipoxygenase and soluble epoxide hydrolase co-incubated with DHA. [3] At 1 ng/mouse, MaR2 was shown to reduce neutrophil infiltration by 40% in a mouse model of peritonitis, and at 10 pM, MaR2 can enhance human macrophage phagocytosis of zymosan A by 90%. [3] Analytica... |
|
T36218
|
19R(20S)-EpDPA
|
|
|
|
19R(20S)-EpDPA is an oxylipin and a metabolite of docosahexaenoic acid .1,2It is formed from DHA by various cytochrome P450 (CYP) isoforms in a stereoselective manner.219R(20S)-EpDPA (30 nM) prevents calcium-induced increases in the spontaneous beating of isolated neonatal rat cardiomyocytes (NRCMs).3
1.Cinelli, M.A., Yang, J., Scharmen, A., et al.Enzymatic synthesis and chemical inversion provide both enantiomers of bioactive epoxydocosapentaenoic acidsJ. Lipid Res.59(11)2237-2252(2018) 2.Lucas... |
|
T35497
|
(±)7(8)-EpDPA
|
|
|
|
Docosahexaenoic acid is the most abundant ω-3 fatty acid in neural tissues, especially in the brain and retina. (±)7(8)-EpDPA is an epoxide derivative of DHA that is generated by the action of cytochrome P450 epoxygenases. It is naturally occurring in plasma and brain and spinal cord tissues and is increased following dietary supplementation with ω-3 fatty acids. (±)7(8)-EpDPA and other epoxy metabolites of DHA modulate receptor and channel activities to evoke diverse effects, such as promoting ... |
|
T37301
|
PCTR2
|
|
|
|
Protein conjugates in tissue regeneration 2 (PCTR2) is a specialized pro-resolving mediator (SPM) synthesized from docosahexaenoic acid . DHA is oxidized to 16S,17S-epoxy-protectin, which is converted to PCTR1 by glutathione S-transferase and to PCTR2 via γ-glutamyl transpeptidase. PCTR2 is found in resolving mouse exudate and in both M1 and M2 macrophages differentiated from isolated human monocytes. |
|
T37633
|
17-oxo-4(Z),7(Z),10(Z),13(Z),15(E),19(Z)-Docosahexaenoic Acid
|
|
|
|
17-oxo-4(Z),7(Z),10(Z),13(Z),15(E),19(Z)-Docosahexaenoic acid is a metabolite of lipoxygenase-mediated oxidation of DHA that is produced endogenously by aspirin-enhanced COX-2 activity. It has been shown to activate Nrf2-dependent antioxidant gene expression, to act as a PPARγ agonist (EC50 = ~200 nM), and to inhibit pro-inflammatory cytokine and nitric oxide production at biological concentration ranges (5-25 μM). |
|
T37241
|
(±)4(5)-EpDPA methyl ester
|
|
|
|
(±)4(5)-EpDPA methyl ester is a derivative of (±)4(5)-EpDPA which is stable enough to ship and handle routinely. The active free acid can be regenerated from the methyl ester by careful base hydrolysis. (±)4(5)EpDPA is a CYP450 metabolite of DHA which can be further metabolized to the diol metabolite. There are no published reports on the biological activity of (±)4(5)-EpDPA methyl ester at this time. |
沪公网安备 31010602006700号